Timing is **everything.**

SUCROMATE™ EQUINE:
THE ONLY FDA APPROVED DESLORELIN PRODUCT.

Thorn BioScience L.L.C.

SUCROMATE™ EQUINE; AN FDA APPROVED, INJECTABLE, SUSTAINED RELEASE GnRH ANALOG.

The ability to induce ovulation precisely carries some obvious benefits. Timing ovulation with the breeding of your client's mares—whether AI or live cover—maximizes pregnancy rates and makes for more efficient management of their breeding program. SucroMate™ Equine (deslorelin acetate) is a sustained release, injectable GnRH analog indicated for inducing ovulation within 48 hours of treatment in mares with a follicle between 30 and 40mm in diameter. It's the only FDA approved injectable deslorelin acetate, and high production standards ensure a consistent, reliable, safe product to offer your clients.

Features of SucroMate		Benefits of SucroMate
Contains 1.8 mg/mL deslorelin acetate in a long-acting base	Reliably advances ovulation to within 48hrs, in 80% of mares treated	Increases the efficiency of the breeding operation
Dose determination, field-based efficacy and safety and target animal safety studies involving hundreds of mares in three countries	FDA approved	Veterinarians and owners/managers can have confidence in the reliability and consistent quality of the product
Manufactured according to Current Good Manufacturing Principles	Batch to batch consistency and quality	Veterinarians and owners/managers can have confidence in the product
Raw materials conform to USP standards	Batch to batch consistency and quality	Veterinarians and owners/managers can have confidence in the product
Available from usual veterinary distributors	Clinics can easily purchase and keep supplies on hand	Veterinarians will not lose time requesting compounded supplies

EFFICACY STUDIES

STUDY 1: Compared efficacy of deslorelin acetate at concentrations of 0.45, 0.9, 1.35 and 1.8 mg/mL with each group compared to placebo. There were 10 mares per treatment arm.

Treatment Group	Ovulation by 48 hours
Placebo	20%
SucroMate™ 1.0 mL	90%

CONCLUSION:

The 1.0 mL SucroMate (1.8 mg/mL deslorelin acetate) dose was the most effective for advancing ovulation to within 48 hours following treatment.

STUDY 2: A second study confirmed that 1.8 mg/mL SucroMate was more effective in advancing ovulation compared to a 0.9 mg/mL dose and a 1.35 mg/mL dose.

Treatment Group	Ovulation by 48 hours
Placebo	0% (0/12)
SucroMate™ 1.0 mL	82% (9/11)

CONCLUSIONS:

The 1.0 mL SucroMate (1.8 mg/mL deslorelin acetate) dose was the most effective for advancing ovulation to within 48 hours following treatment.

There was no detrimental effect on the cycle of administering SucroMate on 3 consecutive cycles.

STUDY 3: Field Based Safety and Efficacy Study.

- A six site, blinded, controlled, multi-centered field efficacy study.
- Mares were randomly assigned into two groups: a single injection of either 1.0 mL of either saline or 1.0 mL SucroMate (1.8 mg/mL deslorelin acetate).
- Breeds included: 23 (8%) Standardbreds, 159 (56%) Thoroughbreds, 98 (35%) Quarter horses and 3 (1%) Paint horses.
- Route of administration: Intramuscularly into the fleshy part of the neck using an 18–21 gage needle.
- Parameters measured: percentage of mares ovulating within 48 hours following injection, as measured by ultrasound per rectum.
- Time to ovulation was calculated from day of treatment to day of ovulation in 24hr increments.
- Additional parameters measured: Percentage of mares that became pregnant following treatment and breeding in any ovulatory period. Mares were followed through gestation and all normal and abnormal deliveries were recorded.
- The number of estrus cycles required for mares to become pregnant was recorded.
- Injection sites were examined for signs of swelling, sensitivity to touch and skin temperature elevation daily for the first 7 days and then at 14 and 21 days post treatment.

EFFICACY RESULTS:

Treatment	No. Cycles	No. Mares	% Ovulated by 48 hours
Placebo	131	97	27%
SucroMate™	142	94	77%

SAFETY RESULTS:

There was no sensitivity **to the touch** nor increase in skin temperature observed at any injection site in either the placebo or SucroMate treated mares in any cycle.

Slight swelling occurred in the injection site in 3 mares in each treatment group on day 1 in Cycle 1 and 1 mare on days 0 and 3 in Cycle 2.

TARGET ANIMAL SAFETY STUDIES

STUDY 1: Scope of study; to measure effects of 10x dose of SucroMate (1.8 mg/mL deslorelin acetate).

Treatment Groups: 16 mares, reproductively sound, divided into two equal groups; 10 mL SucroMate (1.8 mg/mL deslorelin acetate) and 10 mL saline, IM injections divided into 2 x 5 mL doses in same side of the neck, study duration of 21 days.

Parameters measured: comprehensive physical exam days 0, 3 and 7, behavior, feed and water intake measured twice daily. Parameters recorded included heart rate & rhythm, respiratory rate and skin temperature as well as hematology, serum chemistry, urinalysis, LH and FSH levels. Clinical observations specifically looked for in the study included sweating, tremors, defecation and urination patterns, piloerection, sweating and panting, skin temperature and reactions at injection site.

CONCLUSIONS:

Administration of SucroMate (1.8 mg/mL deslorelin acetate) at 10x the recommended dose resulted in transient swelling, increased sensitivity and increased temperature at the injection sites.

STUDY 2: Scope of study; to evaluate the safety of 1x, 3x, and 5x the dose of SucroMate (1.8 mg/mL deslorelin acetate) in mares during each of three consecutive estrus cycles and the effects on conception rates and early pregnancy.

Treatment Groups: 32 mares, 8 in each treatment group.

CONCLUSIONS:

Some transient injection site swelling was observed.

Thorn BioScience L.L.C.

SucroMate™ is manufactured and marketed by Thorn BioScience, Louisville, KY, a division of CreoSalus. 1-800-456-1403

SucroMate Equine contains 1.8 mg/mL deslorelin acetate.

Dose: 1 mL administered IM
Pack size: 10 mL vial (10 doses)

Store refrigerated at 2–8°C

Criteria for administration:

- In heat 2–3 days based on estrus detection or ultrasound image
- Follicles 30–40 mm
- Soft, open cervix

AVAILABLE FROM: